These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33958523)

  • 1. CDH17+/CDX2+ Can be Helpful in Providing Support for Small Intestinal Origin Versus Pancreatic or Biliary Origin.
    Ma H; Xiao W; Wang M; Shi X
    Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):541-545. PubMed ID: 33958523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
    Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
    Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
    Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
    Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2.
    Altree-Tacha D; Tyrrell J; Haas T
    Arch Pathol Lab Med; 2017 Jan; 141(1):144-150. PubMed ID: 28029907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
    Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
    Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin.
    Bronsert P; Kohler I; Werner M; Makowiec F; Kuesters S; Hoeppner J; Hopt UT; Keck T; Bausch D; Wellner UF
    BMC Cancer; 2013 Sep; 13():428. PubMed ID: 24053229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases.
    Malmros K; Lindholm A; Vidarsdottir H; Jirström K; Nodin B; Botling J; Mattsson JSM; Micke P; Planck M; Jönsson M; Staaf J; Brunnström H
    Virchows Arch; 2024 Aug; 485(2):347-357. PubMed ID: 37349623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of tumor proliferative indices in periampullary cancers: Ki-67, mitotic activity index (MI) and volume corrected mitotic index (M/V) using tissue microarrays.
    Aloysius MM; Hewavisenthi SJ; Bates TE; Rowlands BJ; Lobo DN; Zaitoun AM
    World J Surg; 2010 Sep; 34(9):2115-21. PubMed ID: 20556608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.
    Ge J; Chen Z; Wu S; Yuan W; Hu B; Chen Z
    Clin Oncol (R Coll Radiol); 2008 May; 20(4):275-83. PubMed ID: 18353622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
    Ko S; Chu KM; Luk JM; Wong BW; Yuen ST; Leung SY; Wong J
    J Pathol; 2005 Apr; 205(5):615-22. PubMed ID: 15732140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
    Huang LP; Yu YH; Sheng C; Wang SH
    Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis.
    Ishikawa A; Sasaki M; Ohira S; Ohta T; Oda K; Nimura Y; Chen MF; Jan YY; Yeh TS; Nakanuma Y
    Lab Invest; 2004 May; 84(5):629-38. PubMed ID: 15048136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.
    Adsay NV; Merati K; Basturk O; Iacobuzio-Donahue C; Levi E; Cheng JD; Sarkar FH; Hruban RH; Klimstra DS
    Am J Surg Pathol; 2004 Jul; 28(7):839-48. PubMed ID: 15223952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.
    Hooper JE; Morgan TK; Grompe M; Sheppard BC; Troxell ML; Corless CL; Streeter PR
    Hum Pathol; 2012 Oct; 43(10):1583-9. PubMed ID: 22406361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer.
    Ito R; Oue N; Yoshida K; Kunimitsu K; Nakayama H; Nakachi K; Yasui W
    Virchows Arch; 2005 Oct; 447(4):717-22. PubMed ID: 16044349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumorigenesis and phenotypic characteristics of mucin-producing bile duct tumors: an immunohistochemical approach.
    Nakanuma Y; Zen Y; Harada K; Ikeda H; Sato Y; Uehara T; Sasaki M
    J Hepatobiliary Pancreat Sci; 2010 May; 17(3):211-22. PubMed ID: 19680592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
    Saad RS; Silverman JF; Khalifa MA; Rowsell C
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.
    Xue Y; Vanoli A; Balci S; Reid MM; Saka B; Bagci P; Memis B; Choi H; Ohike N; Tajiri T; Muraki T; Quigley B; El-Rayes BF; Shaib W; Kooby D; Sarmiento J; Maithel SK; Knight JH; Goodman M; Krasinskas AM; Adsay V
    Mod Pathol; 2017 Feb; 30(2):255-266. PubMed ID: 27739441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cadherin-17 (CDH17) expression in human cancer: A tissue microarray study on 18,131 tumors.
    Jacobsen F; Pushpadevan R; Viehweger F; Freytag M; Schlichter R; Gorbokon N; Büscheck F; Luebke AM; Putri D; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Bernreuther C; Lebok P; Sauter G; Minner S; Steurer S; Simon R; Burandt E; Dum D; Lutz F; Marx AH; Krech T; Clauditz TS
    Pathol Res Pract; 2024 Apr; 256():155175. PubMed ID: 38452580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cadherin 17 in well-differentiated neuroendocrine tumours.
    Snow AN; Mangray S; Lu S; Clubwala R; Li J; Resnick MB; Yakirevich E
    Histopathology; 2015 Jun; 66(7):1010-21. PubMed ID: 25388236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.